Relapsed/refractory follicular lymphoma (R/R FL) is challenging to treat, requiring thoughtful clinical decision-making during treatment selection and sequencing. In this episode, CANCER BUZZ speaks with Benjamin Heyman, MD, hematologist and clinical associate professor at City of Hope, about the importance of individualized care, shared decision-making, clinical trial referrals, and multidisciplinary collaboration. CANCER BUZZ also speaks with Laurie Adami, patient advocate with R/R FL, about her real-world experience with multiple lines of therapy, clinical trials, and patient advocacy.

"There are lots of options available, which is really great for patients, so you get to have a good conversation with patients about what they value." - Benjamin Heyman, MD

"The medications you receive in clinical trials may not be the standard of care today, but it may be the standard of care 5 years from now." - Benjamin Heyman, MD

"Patient advocacy organizations have patients that can talk to you. They know what you're talking about. They're on the road ahead of you." - Laurie Adami

Guest:

Benjamin Heyman, MD

Hematologist

Clinical Associate Professor

City of Hope

San Diego, CA

Laurie Adami

R/R FL Patient Advocate

Los Angeles, LA

Received care at UCLA Lymphoma Program

Additional Reading/Sources

ACCC Follicular Lymphoma

Effective Practice Guide: Multidisciplinary Approaches to Treating Patients With R/R FL

Putting Guidance Into Practice: Real-World Approaches to Relapsed/Refractory Folicular Lymphoma

ACCC's Community Oncology Research Institute